|
2024
|
Invention
|
Hormone receptor modulators for treating metabolic conditions and disorders.
The invention rela... |
|
|
Invention
|
Compounds and methods for treating hyperkalemia.
The present invention provides a compound of fo... |
|
|
Invention
|
Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists.
The invention relates to ... |
|
|
Invention
|
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associat... |
|
|
Invention
|
Nhe3-binding compounds and methods for inhibiting phosphate transport.
Provided are NHE3-binding... |
|
2023
|
Invention
|
Compounds useful for treating gastrointestinal tract disorders. The present disclosure is directe... |
|
|
Invention
|
Compounds and methods for inhibiting phosphate transport.
Provided are non-NHE3-binding agents h... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations for the treatment of hyperphosphatemia; ... |
|
|
Invention
|
Intestinal epithelial cell cultures.
Provided are compositions and methods for generating two-di... |
|
|
Invention
|
Glycyrrhetinic acid derivatives for treating hyperkalemia.
The present invention provides a comp... |
|
2022
|
Invention
|
Methods for inhibiting phosphate transport.
The present invention relates to methods for lowerin... |
|
|
G/S
|
Pharmaceuticals and medical preparations; Dietetic food and substances adapted for medical use, f... |
|
|
Invention
|
Hormone receptor modulators for treating metabolic conditions and disorders. The invention relate... |
|
2021
|
Invention
|
Compounds useful for treating gastrointestinal tract disorders.
The present disclosure is direct... |
|
|
Invention
|
Oral formulation of a therapeutic compound.
The present invention provides a pharmaceutical tabl... |
|
|
Invention
|
Oral formulations of tenapanor. The present invention provides a pharmaceutical tablet formulatio... |
|
|
G/S
|
Pharmaceutical preparations for the treatment and prevention
of hyperphosphatemia. |
|
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of hyperphosphatemia. |
|
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of hyperphosphatemia |
|
|
Invention
|
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators. The disclosure relat... |
|
|
Invention
|
Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists. The invention relates to n... |
|
2020
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of hyperphosphatemia |
|
|
G/S
|
Pharmaceutical preparations for the treatment of renal and cardiovascular diseases, disorders, ai... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of renal and
cardiovascular diseases, disorders, a... |
|
|
G/S
|
pharmaceutical preparations for the treatment and prevention of hyperphosphatemia. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of renal, cardiovascular, endocrine, hepatic, metab... |
|
|
Invention
|
Hormone receptor modulators for treating metabolic conditions and disorders.
The invention relat... |
|
|
Invention
|
Combination for lowering serum phosphate in a patient. The present invention relates to methods f... |
|
|
Invention
|
Glycyrrhetinic acid derivatives for use in treating hyperkalemia. 4, are as defined herein. The c... |
|
|
Invention
|
Glycyrrhetinic acid derivatives for use in treating hyperkalemia. 12344, are as defined herein. T... |
|
|
Invention
|
Glycyrrhetinic acid derivatives for use in treating hyperkalemia. The present invention provides ... |
|
2019
|
Invention
|
Compounds and methods for inhibiting phosphate transport. Provided are non-NHE3-binding agents ha... |
|
|
Invention
|
Nhe3-binding compounds and methods for inhibiting phosphate transport. Provided are NHE3-binding ... |
|
2018
|
Invention
|
Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorder... |
|
|
Invention
|
Glycyrrhetinic acid derivatives for treating hyperkalemia. 4, are as defined herein. These compou... |
|
|
Invention
|
Glycyrrhetinic acid derivatives for treating hyperkalemia. The present invention provides a... |
|
|
Invention
|
Glycyrrhetinic acid derivatives for treating hyperkalemia. 12344, are as defined herein. These co... |
|
|
Invention
|
Treatment of hepatic disorders. The invention relates to the use of GLP-2 or an analog thereof in... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of renal,
cardiovascular, endocrine, hepatic, meta... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of renal, cardiovascular, and respiratory condition... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of renal, cardiovascular and respiratory conditions... |
|
|
Invention
|
Inhibitors of nhe-mediated antiport. The present disclosure is directed to compounds (I′) and to ... |
|
|
Invention
|
Inhibitors of nhe-mediated antiport. The present disclosure is directed to compounds (Ι') and to ... |
|
|
Invention
|
Inhibitors of nhe-mediated antiport. The present disclosure is directed to compounds (?') and to ... |
|
2017
|
G/S
|
Pharmaceutical preparations for the treatment and prevention
of irritable bowel syndrome, chroni... |
|
|
Invention
|
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators. 4 are described here... |
|
|
Invention
|
Hormone receptor modulators for treating metabolic conditions and disorders. 3 are described here... |
|
|
Invention
|
Compositions and methods for treating hyperkalemia.
The present invention is directed to composi... |
|
|
G/S
|
pharmaceutical preparations for the treatment and prevention of irritable bowel syndrome, chronic... |
|
|
G/S
|
pharmaceutical preparations for the treatment and prevention of hyperphosphatemia |
|
2013
|
G/S
|
Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic ... |
|
2008
|
G/S
|
pharmaceutical preparations for the treatment of renal * and * cardiovascular [, endocrine, hepat... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of gastrointestinal conditions, diseases, disorders... |
